Search results for "Atrial"

showing 10 items of 564 documents

A re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.

2015

The common atrioventricular nodal re-entry tachycardia is the most common form of paroxysmal supraventricular tachycardia. It starts frequently with a supraventricular ectopic beat that, on finding the fast pathway in refractory period, travels in the slow pathway as to appear as a prolongation of the PR interval on the ECG. In this study, we show a singular case of a common atrioventricular nodal re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.

MaleTachycardiacongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtySettore MED/09 - Medicina InternaRefractory periodSlow pathwayEctopic beatParoxysmal supraventricular tachycardiaElectrocardiographyInternal medicineTachycardia Supraventricularmedicinere-entry tachycardia atrial tachycardiaHumansTachycardia Atrioventricular Nodal Reentrycardiovascular diseasesAtrial tachycardiaAgedFast pathwaybusiness.industryRe entryGeneral Medicinemedicine.diseasesurgical procedures operativecardiovascular systemCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Progression From Paroxysmal to Persistent Atrial Fibrillation. Clinical Correlates and Prognosis

2010

Objectives: We investigated clinical correlates of atrial fibrillation (AF) progression and evaluated the prognosis of patients demonstrating AF progression in a large population. Background: Progression of paroxysmal AF to more sustained forms is frequently seen. However, not all patients will progress to persistent AF. Methods: We included 1,219 patients with paroxysmal AF who participated in the Euro Heart Survey on AF and had a known rhythm status at follow-up. Patients who experienced AF progression after 1 year of follow-up were identified. Results: Progression of AF occurred in 178 (15%) patients. Multivariate analysis showed that heart failure, age, previous transient ischemic attac…

MaleTime FactorPrognosiRisk FactorpredictionMiddle AgedRisk AssessmentSeverity of Illness IndexAtrial FibrillationDisease ProgressionepidemiologyFemaleatrial fibrillation; epidemiology; prediction; prognosis; progression; Aged; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Disease ProgressionprogressionAgedHuman
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

Results of mitral valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus conventional median sternotomy: a randomized …

2011

Objective: The results of mitral repair for complex Barlow valves are adequate and support earlier intervention. It is unknown whether these results are reproducible in the context of minimally invasive surgery via right minithoracotomy. Methods: We randomized patients with Barlow mitral disease (bileaflet prolapse) to have conventional open repair via median sternotomy (MS group) or minimally invasive (MI group) repair. Repair was done using polytetrafluoroethylene chordal reimplantation for both leaflets. In the MI group, we adopted right minithoracotomy, peripheral cannulation, external aortic clamping, and surgery under direct vision. Results: Both groups comprised 70 patients. The oper…

MaleTime Factorsmedicine.medical_treatmentKaplan-Meier Estimatelaw.inventionlawRisk FactorsMitral valveCardiac Surgical ProcedureHospital MortalityProspective StudiesUltrasonographyPain PostoperativeMitral Valve ProlapseAtrial fibrillationGenetic Diseases X-LinkedMiddle Agedmedicine.anatomical_structureTreatment OutcomeItalyThoracotomyCardiologyMitral ValveFemaleCardiology and Cardiovascular MedicineHumanPulmonary and Respiratory MedicineAdultReoperationmedicine.medical_specialtyTime FactorContext (language use)Risk AssessmentInternal medicineCardiopulmonary bypassmedicineHumansCardiac Surgical ProceduresMechanical ventilationMitral valve repairMitral regurgitationChi-Square Distributionbusiness.industryRisk FactorPatient SelectionSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSternotomySurgeryProspective StudieMedian sternotomySurgerybusinessThe Journal of thoracic and cardiovascular surgery
researchProduct

Atrial fibrillation is associated with cardiac hypoxia.

2008

BACKGROUND: Atrial fibrillation (AF), the most common human arrhythmia, is responsible for substantial morbidity and mortality and may be promoted by selective atrial ischemia and atrial fibrosis. Consequently, we investigated markers for hypoxia and angiogenesis in AF. METHODS: Right atrial appendages (n=158) were grouped according to heart rhythm [sinus rhythm (SR) or AF]. The degree of fibrosis and microvessel density of all patients were determined morphometrically using Sirius-Red- and CD34/CD105-stained sections, respectively. Next, sections (n=77) underwent immunostaining to detect hypoxia- and angiogenesis-related proteins [hypoxia-inducible factor (HIF)1 alpha, HIF2 alpha, vascular…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyCytoplasmAngiogenesisIschemiaMyocardial IschemiaBiologyPathology and Forensic Medicinechemistry.chemical_compoundFibrosisInternal medicineAtrial FibrillationmedicineBasic Helix-Loop-Helix Transcription FactorsHumansSinus rhythmAtrial AppendageHypoxiaMicrovesselAgedCell NucleusNeovascularization PathologicMicrocirculationMyocardiumAtrial fibrillationGeneral MedicineHypoxia (medical)Middle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCoronary VesselsFibrosisUp-RegulationVascular endothelial growth factorEndocrinologychemistryCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicineBiomarkersCardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
researchProduct

Presence of Oxytocin, Vasopressin and Atrial Natriuretic Peptide and Their Modification in Rat Hypothalamic Paraventricular Nucleus During Resistance…

2013

Summary Many studies have demonstrated the physiological effects of oxytocin (OT), atrial natriuretic peptide (ANP) and vasopressin (VP) in the homoeostasis of body fluids during physical exercise. However, a little information is available about the related immunohistochemical changes in hypothalamic magnocellular neurosecretory system during and after the training. The aim of the present work was to study the immunohistochemical changes in OT, ANP and VP levels in the hypothalamic paraventricular nucleus during and after resistance exercise protocol. Three groups of Wistar rats were trained by a rung ladder protocol for 15, 30 and 45 days, respectively; a fourth group was left to rest for…

MaleVasopressinmedicine.medical_specialtyVasopressinsPeriod (gene)Physical exerciseOxytocinAtrial natriuretic peptidePhysical Conditioning AnimalInternal medicinemedicineAnimalsRats WistarNeuronsBody fluidGeneral Veterinarybusiness.industryOxytocin vasopressinANPbrainResistance TrainingGeneral MedicineRatsmedicine.anatomical_structureEndocrinologyGene Expression RegulationOxytocinsense organsbusinessNucleusAtrial Natriuretic Factorhormones hormone substitutes and hormone antagonistsHomeostasisParaventricular Hypothalamic Nucleusmedicine.drugAnatomia, Histologia, Embryologia
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2013

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyMESH: Intention to Treat AnalysisMESH: Venous Thromboembolism0302 clinical medicineMESH: Aged 80 and overRecurrence030212 general & internal medicineMESH: WarfarinAged 80 and overMESH: AgedMESH: Middle AgedMESH: RiskHazard ratioAtrial fibrillationVenous ThromboembolismGeneral MedicineMESH: Follow-Up StudiesMiddle AgedIntention to Treat Analysis3. Good healthPulmonary embolismMESH: International Normalized RatioMESH: beta-AlanineMESH: Young AdultAnesthesiaFemaleMESH: Hemorrhagemedicine.drugAdultRiskAdolescentHemorrhageLower riskPlaceboDabigatranDabigatran Venous ThromboembolismYoung Adult03 medical and health sciencesmedicineHumansInternational Normalized RatioAgedMESH: AdolescentIntention-to-treat analysisMESH: Humansbusiness.industryWarfarinMESH: Adultmedicine.diseaseMESH: MaleMESH: Recurrencebeta-AlanineBenzimidazolesWarfarinbusinessMESH: BenzimidazolesVenous thromboembolismMESH: FemaleFollow-Up Studies
researchProduct

Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose ou…

2018

Summary Non-vitamin K antagonist oral anticoagulants (NOACs) – dabigatran, rivaroxaban, apixaban and edoxaban – are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When prescribed incorrectly, NOACs are associated with an increased risk of ischaemic events and bleeding. Current NOAC labels explicitly address dose adjustments according to age, body weight, renal function and concomitant treatment with P-glycoprotein inhibitors. The required dose adjustments vary significantly from molecule to molecule, thereby creating a complex dose adjustment environment. Furthermore, recommendations suppor…

Male[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRisk FactorsEdoxabanAtrial FibrillationDrug Dosage Calculations030212 general & internal medicineStrokeComputingMilieux_MISCELLANEOUSAged 80 and over[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAtrial fibrillationGeneral MedicineMiddle AgedVitamin K antagonist[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthStroke[SDV] Life Sciences [q-bio]Treatment OutcomeAnesthesiaFemaleApixabanCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtymedicine.drug_classClinical Decision-MakingHemorrhageDabigatran03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansIntensive care medicineBlood CoagulationAgedHAS-BLEDRivaroxabanDose-Response Relationship Drugbusiness.industryPatient SelectionAnticoagulantsmedicine.diseasechemistrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct